The company has a deep-rooted academic heritage built on 20 years of pioneering research led by the members of the UCL Liver Failure Group. The Scientific founder is a world-renowned hepatologist with decades of experience in advanced liver disease. The company’s platform integrates technical expertise, clinical trial design and execution with its global collaborator network to accelerate development.
Capital raise: £3 million GBP
Headquarters: Herefordshire, England
Type of Entity: Series A company
Use of proceeds: Expansion
Annual revenue: £34m GBP
Min. ticket size: £500K GBP